Perihilar cholangiocarcinoma
Conditions
Interventions
ALBI1 group:None
ALBI2 group:None
ALBI3 group:None
Sponsors
Henan Provincial People's Hospita,medical
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with pCCA before surgery, have the conditions to complete radical resection of the tumor, and there is no substantial tumor invasion in the left and right trunks of the portal vein; 2. Intraoperative exploration confirmed that the tumor was mainly located in the central area of the hilar part of the liver, and had not yet extensively invaded one side of the liver parenchyma, and there was no tumor invasion of the main trunk, bifurcation and secondary branches of the extrahepatic portal vein; 3. Postoperative pathological confirmation of pCCA; 4. Age>=18 years old, male or female; 5. Have sufficient comprehension ability, voluntarily sign the informed consent form to participate in clinical research, and be able to actively cooperate with the treatment plan and follow-up process.
Exclusion criteria
Exclusion criteria: 1. Severe cardiopulmonary insufficiency, renal insufficiency, etc., which in the opinion of the investigator may affect the treatment, follow-up or evaluation of patients; 2. Intraoperative exploration found that the tumor had bilateral intrahepatic metastasis, distant organ metastasis or intra-abdominal implant metastasis, and there was no condition for radical tumor resection; 3. Bilateral portal vein involvement, portal vein bifurcation or trunk involvement is extensive, and vasoresectic reconstruction is not possible; 4. Have any other serious illness that, in the opinion of the investigator, may affect the treatment, follow-up or evaluation of the patient. Including any uncontrolled clinically significant neurological, psychiatric, immunomodulatory, metabolic and infectious diseases; 5. Patients with prior or concurrent occurrence of other malignancies, with the following exceptions: carcinoma in situ of cervical cancer or breast cancer, after curative therapy, with no signs of recurrence for at least 3 years prior to the study, and the primary malignancy has been completely resected and in complete remission> = 5 years; 6. Anti-tumor therapy (including chemotherapy, small molecule targeting, and clinical drug trials) before enrollment; 7. Study participants need dialysis and other subjects who are considered by the investigator to be unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90-day postoperative mortality rate;Incidence of postoperative liver failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-free survival;Overall survival;Incidence of serious postoperative complications; | — |
Countries
China
Contacts
Public ContactQin Tao
Henan Provincial People's Hospita,medical
Outcome results
None listed